Cambridge, MA, December 19, 2016 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, announced today that Colonel (retired) Dallas C. Hack, MD, MPH has joined the company’s Scientific Advisory Board. Astrocyte Pharmaceuticals is developing novel small molecule therapeutics for acute administration to patients who have suffered a stroke, traumatic brain injury (TBI) or concussion.
“Over the past decade, Col. Hack has been the leading visionary on how to best advance brain trauma research across the public and private sectors. His leadership has transformed and modernized the field of TBI research and patient care,” said William Korinek, CEO at Astrocyte Pharmaceuticals. “We are honored to have Col. Hack join the Astrocyte team,”
Col. Hack previously served as Senior Medical Advisor to the Principal Assistant, Research and Technology, US Army Medical Research and Materiel Command (USAMRMC) from 2014 to 2015, where he was responsible for coordinating research that would reduce morbidity and save the lives of troops injured in the line of duty. From 2008 to 2014, Col. Hack was the Director of the Combat Casualty Care Research Program (CCCRP) at USAMRMC where he coordinated TBI research across the Department of Defense including overseeing 650 TBI research projects and the application of over $850 million in federal funds. Col. Hack was instrumental in establishing the 2013 National Research Action Plan on TBI and PTSD, the Chronic Effects of Neurotrauma Consortium, and the NCAA-DoD Grand Alliance.
“Brain injuries are a leading cause of death of disability, and it is imperative that we develop new agents that will limit the neuronal damage that these millions of patients suffer,” said Col. Hack. “Astrocyte has a novel approach and a promising drug, and I am excited to help advance this therapeutic to patients.”
For more information about Astrocyte Pharmaceuticals please contact Dr. William Korinek at 617-444-8765 or email@example.com.
About Astrocyte Pharmaceutical Inc.
Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.